title: A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
abstract: This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine-associated weight gain.
  
  
  METHODS
  This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects.
  
  
  RESULTS
  Ten patients were enrolled into the placebo group and 11 patients into the sibutramine group. There were no significant baseline differences between the two groups on age, gender, education, ethnicity, diagnosis, weight, body mass index (BMI), and blood pressure. At week 12, there were no significant differences in changes in weight, BMI, abdominal and waist circumferences, Hba1c, fasting glucose, or cholesterol levels.
  
  
  CONCLUSIONS
  Sibutramine treatment did not show significant weight loss compared with placebo in clozapine-treated patients with schizophrenia or schizoaffective disorder. Further research with a larger sample size and longer follow-up duration is warranted.
authors.affiliation: The Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA. dchenderson@partners.org
authors.forename: D C
authors.initials: DC
authors.lastname: Henderson
authors.forename: X
authors.initials: X
authors.lastname: Fan
authors.forename: P M
authors.initials: PM
authors.lastname: Copeland
authors.forename: C P
authors.initials: CP
authors.lastname: Borba
authors.forename: T B
authors.initials: TB
authors.lastname: Daley
authors.forename: D D
authors.initials: DD
authors.lastname: Nguyen
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: D
authors.initials: D
authors.lastname: Hayden
authors.forename: O
authors.initials: O
authors.lastname: Freudenreich
authors.forename: C
authors.initials: C
authors.lastname: Cather
authors.forename: A E
authors.initials: AE
authors.lastname: Evins
authors.forename: D C
authors.initials: DC
authors.lastname: Goff
mesh_terms: D000328:Adult; D000886:Anthropometry; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001067:Appetite Depressants / Q000494:pharmacology* / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D003503:Cyclobutanes / Q000494:pharmacology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced* / Q000188:drug therapy* / Q000378:metabolism; D011618:Psychotic Disorders / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001067:Appetite Depressants; D001786:Blood Glucose; D002784:Cholesterol; D003024:Clozapine; D003503:Cyclobutanes; D006442:Glycated Hemoglobin; D006454:Hemoglobins; C517652:hemoglobin A1c protein, human; C058254:sibutramine